Neonatal Respiratory Physiology and Disorders

📚 03 Neonatology ‱ 🎯 20 High-Yield MCQs ‱ Nelson 22nd Edition Standard

Neonatal Resuscitation & Stabilization

  • Initial Resuscitation FiO₂ for Very Preterm Infants: ((NRESP001)): Very preterm infants (<32 weeks of gestation) must be resuscitated with low initial oxygen concentrations starting at FiO₂ >30% ((NRESP001)). 100% oxygen is strictly contraindicated as an initial strategy due to severe oxidative injury and free radical damage ((NRESP001)).
  • Indications for Chest Compressions: ((NRESP002)): Chest compressions are indicated only if the heart rate remains <60 beats/min after at least 30 seconds of effective positive pressure ventilation (PPV) ensuring adequate chest rise ((NRESP002)). A heart rate between 60–100/min mandates optimizing ventilation, not immediate chest compressions or epinephrine ((NRESP002)).

Respiratory Disorders & Physiology in Preterm/Term Neonates

  • Antenatal Corticosteroid Therapy & RDS Prevention: ((((NRESP004)) · ((NRESP019)) · ((NRESP020)))): Antenatal corticosteroids (e.g., betamethasone) are the most effective preventive strategy for respiratory distress syndrome (RDS), significantly decreasing RDS, intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and neonatal mortality (((NRESP004)) · ((NRESP019))). ACOG guidelines recommend a single course of antenatal corticosteroids even for late preterm gestations (34⁰⁄₇ to 36⁶⁄₇ weeks) at risk of delivery within 7 days if not previously given ((NRESP020)). Patent ductus arteriosus (PDA) rate is not significantly reduced by antenatal steroids ((NRESP019)).
  • Surfactant Physiology & Pool Deficit: ((((NRESP005)) · ((NRESP008)) · ((NRESP017)))): Preterm neonates have a severely depleted endogenous surfactant pool of approximately 10 mg/kg, compared to 100 mg/kg in term infants ((NRESP005)). Pulmonary surfactant is synthesized, stored in lamellar bodies, and secreted by type II alveolar epithelial cells (type II pneumocytes) ((NRESP008)). The principal surface-active constituent that lowers surface tension to near-zero at end-expiration is dipalmitoyl phosphatidylcholine (DPPC), a subtype of phosphatidylcholine ((NRESP017)).
  • Fetal Lung Maturity Testing: ((NRESP007)): The lecithin/sphingomyelin (L/S) ratio assesses fetal lung maturity; an L/S ratio >2 indicates mature type II pneumocyte function and low risk of RDS ((NRESP007)).
  • Stages of Fetal Lung Development: ((NRESP009)): The presence of terminal bronchioles dividing into respiratory bronchioles, alveolar ducts, and primitive alveoli characterizes the canalicular phase, establishing the structural basis for future gas exchange ((NRESP009)).
  • Surfactant Preparations: ((NRESP010)): Lucinactant (SurfaxinÂź) is a second-generation synthetic surfactant containing SP-B analogues (sinapultide), developed to eliminate risks of animal protein exposure, infection, and inactivation ((NRESP010)). In contrast, beractant and poractant alfa are natural animal-derived extracts ((NRESP010)).
  • Maternal Diabetes and RDS Risk: ((NRESP011)): Maternal diabetes mellitus delays fetal lung maturation by inducing fetal hyperinsulinemia, which competitively antagonizes cortisol action and inhibits surfactant synthesis, placing the infant at heightened risk for RDS even at later gestational ages ((NRESP011)).

Transient Tachypnea of the Newborn (TTN) & Air Leak Syndromes

  • Transient Tachypnea of the Newborn (TTN): ((((NRESP006)) · ((NRESP013)))): Caused by delayed clearance of fetal lung fluid (classic after elective cesarean section without labor) ((NRESP013)). Lung ultrasound characteristically demonstrates the double lung point, showing a sharp boundary between aerated superior lung fields and basal interstitial edema ((NRESP006)). Chest X-ray reveals hyperinflation and fluid in the interlobar fissures without air bronchograms ((NRESP013)). The condition is benign and typically resolves spontaneously within 48–72 hours ((NRESP013)).
  • Pneumothorax in Meconium Aspiration Syndrome (MAS): ((NRESP012)): MAS causes ball-valve airway obstruction and air trapping; concurrent use of positive pressure support (like CPAP) massively increases the risk of pneumothorax, manifesting as sudden clinical deterioration and asymmetric chest movement ((NRESP012)).

Ventilator-Associated Complications & Congenital Malformations

  • Ventilator-Associated Pneumonia (VAP): ((NRESP014)): Defined as nosocomial pneumonia developing ≄48 hours after the initiation of invasive mechanical ventilation via endotracheal intubation ((NRESP014)).
  • Inhaled Nitric Oxide (iNO) Mechanisms: ((NRESP015)): iNO acts as a pulmonary vasodilator, improves V/Q matching, promotes alveolarization, reduces inflammation, and protects against surfactant protein dysfunction ((NRESP015)). iNO decreases abnormal pulmonary vascular remodeling; hence, an "increase in vascular remodeling" is false ((NRESP015)).
  • Congenital Lobar Emphysema (CLE): ((NRESP016)): Also known as congenital lobar hyperinflation, characterized by progressive overdistension of one or more pulmonary lobes (most commonly upper/middle lobes) due to deficient bronchial cartilage, causing hyperlucency on chest radiography, mediastinal shift, and severe respiratory compromise ((NRESP016)).
  • Neonatal Feeding Adaptation: ((NRESP018)): The high laryngeal position in newborns brings the epiglottis close to the soft palate, anatomically separating the respiratory and digestive pathways and enabling simultaneous sucking, swallowing, and breathing without aspiration ((NRESP018)).
  • Apnea of Prematurity Resolution: ((NRESP003)): Apnea of prematurity typically resolves by 36–37 weeks post-menstrual age (PMA) in infants born at or after 28 weeks gestation as respiratory control matures ((NRESP003)).